Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

News Daily News

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

February 14, 2025

TEMPO-2: Tenecteplase No Help in Mild Stroke With Proven Occlusion

News Conference News ESOC 2024

TEMPO-2: Tenecteplase No Help in Mild Stroke With Proven Occlusion

May 23, 2024

Some Daylight for Vitamin D? New Analysis Hints at Small CVD Benefit

News Daily News

Some Daylight for Vitamin D? New Analysis Hints at Small CVD Benefit

Michael O'Riordan

June 30, 2023

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

News Conference News EAS 2023

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Michael O'Riordan

May 24, 2023

Vitamin D Doesn’t Reduce Statin-Associated Muscle Symptoms VITAL

News Daily News

Vitamin D Doesn’t Reduce Statin-Associated Muscle Symptoms: VITAL

Michael O'Riordan

November 25, 2022

USPSTF: Most Vitamin, Supplement Data Still ‘Inconclusive’ on CVD Benefits

News Daily News

USPSTF: Most Vitamin, Supplement Data Still ‘Inconclusive’ on CVD Benefits

Yael L. Maxwell

June 23, 2022

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

News Conference News ESC 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

Michael O'Riordan

August 30, 2021

Elective Revascularization, Better Long-term Survival: Meta-analysis

News Conference News EuroPCR 2021

Elective Revascularization, Better Long-term Survival: Meta-analysis

Michael O'Riordan

May 18, 2021

FDA Approves Evinacumab for Rare Homozygous FH

News Daily News

FDA Approves Evinacumab for Rare Homozygous FH

Michael O'Riordan

February 11, 2021

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

News Daily News

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

Michael O'Riordan

July 09, 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

Quality of CAD Care Varies by Type of Medicare Coverage

News Daily News

Quality of CAD Care Varies by Type of Medicare Coverage

February 20, 2019

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

Spin to Win: Results From Late Breaking Meeting Trials Often Overstated

News Daily News

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

May 15, 2018

News Daily News

ITALIC Published: No Benefit to Long-Term DAPT After Stenting

Yael L. Maxwell

March 10, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.